Bristol-Myers beats profit, sales forecasts
Oct 23 (Reuters) - Bristol-Myers Squibb Co reported better-than-expected quarterly earnings, fueled by strong sales of cancer and diabetes drugs, but stuck to its earlier full-year 2013 profit forecast.
The company on Wednesday said it earned $692 million, or 42 cents per share in the third quarter. That compared with a loss of $711 million, or 43 cents per share, in the year-earlier period when the company took a big charge for an experimental hepatitis C drug that showed disappointing results in clinical trials.
Excluding special items, Bristol-Myers earned 46 cents per share. Analysts, on average, expected 44 cents per share, according to Thomson Reuters I/B/E/S.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Target cyber breach hits 40 million payment cards at holiday peak |
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- New York Mayor-elect's reputation for lateness parodied on Twitter
- Putin critic Khodorkovsky free after pardon |